Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvsef crawled date : 2022 - 03 - 25 save search
Worldwide Malaria Diagnostics Industry to 2026 - Featuring Access Bio, Novartis and Olympus Among Others
Published: 2022-03-25 (Crawled : 21:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NINOF | $10.245 -14.1% 100
|
Consumer Durables
| Email alert
Add to watchlist
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
| Email alert
Add to watchlist
DHR | $250.41 -1.07% -0.72% 3.3M
|
Health Technology
| Email alert
Add to watchlist
NINOY | $10.27 -3.3% 150K
|
Manufacturing
| Email alert
Add to watchlist
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
| Email alert
Add to watchlist
novartis diagnostics diagnostic malaria
Drugs for Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 18:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -6.55%
H: 7.81%
C: 7.56%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.28%
H: 1.09%
C: 0.18%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.58%
H: 1.16%
C: 0.23%
immunotherapy report market drug
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Cellular Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 14:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
immunotherapy report market
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.